바로가기  >

Abstract

PURPOSE:
We conducted this study to evaluate the outcomes of external-beam radiotherapy tumor boost (EBRT-B) in cervical cancerpatients who could not receive intracavitary brachytherapy.

METHODS:
A total of 11 hospitals provided the data of patients who received EBRT-B during the period from January 2005 through October 2012.

RESULTS:
A total of 75 patients were included. The median radiotherapy dose was 46 Gy (range, 40-54 Gy) for whole pelvis and 24 Gy (range, 9-35 Gy) for EBRT-B. Initial tumor responses assessed at 2 to 6 months after radiotherapy were as follows: 46 with complete response, 22 with partial response, 2 with stable disease, and 3 with progressive disease. After a median follow-up time of 33 months, 30 patients (40.0%) showed disease progression including 21 (28.0%) with local progression. The 5-year local failure-free survival rate was 70.0%. Achieving complete response at the first follow-up visit and an overall treatment time of 53 days or less were significantly related to favorable local failure-free survival. The rate of grade 3 or higher toxicity was 2.6%.

CONCLUSIONS:
Approximately 70% of patients had local tumor control after curative radiotherapy using EBRT-B. Early tumor response and overall treatment time of 53 days or less were closely associated with favorable local control.

Author information

Haeyoung Kim, MD,* Young Seok Kim, MD,Þ Ji Hyeon Joo, MD,Þ Keun-Yong Eom, MD,þ
Won Park, MD,§ Jin Hee Kim, MD,|| Jong Hoon Lee, MD,¶ Yeon Sil Kim, MD,# Seok Ho Lee, MD,**
Kijung Ahn, MD,ÞÞ Yong Bae Kim, MD,þþ Me-Yeon Lee, MD,§§ and Sei Kyung Chang, MD||||

*Department of Radiation Oncology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong; †Asan Medical Center, University of Ulsan College of Medicine, Seoul; ‡Seoul National University BundangHospital, Seoungnam; §SamsungMedicalCenter, Sungkyunkwan University School of Medicine, Seoul; ||Dongsan Medical Center, Keimyung University School of Medicine, Daegu; ¶St Vincent’s Hospital, The Catholic University of Korea College of Medicine, Suwon; #The Catholic University of Korea, Seoul; **Gacheon University Gil Hospital, Incheon; ††Inje University College of Medicine, Busan; ‡‡Yonsei Cancer Center, Yonsei University College of Medicine, Seoul; §§Hallym University Sacred Heart Hospital, Anyang; and ||||CHA BundangMedicalCenter,CHAUniversity, Seongnam,Republic of Korea.

Address correspondence and reprint requests to Haeyoung Kim, MD, Department of Radiation Oncology, Hallym University Dongtan Sacred Heart Hospital, 7, Keunjaebong-gil, Hwaseong-si, Gyeonggi-do 18450, Republic of Korea. E-mail: hykim0131@hanmail.net.